Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCN NASDAQ:LNAI NASDAQ:MBRX NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.00-0.3%$3.24$1.03▼$8.48$13.03M1.7843,278 shs23,861 shsLNAILunai Bioworks$2.29-3.4%$2.63$1.21▼$33.50$10.74M0.4140,538 shs22,046 shsMBRXMoleculin Biotech$2.41-2.4%$2.44$1.79▼$24.00$13.18M1.77290,995 shs172,928 shsVIVSVivoSim Labs$1.19$1.41$1.13▼$5.30$3.10M1.3852,469 shs38,431 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+1.01%-2.27%-2.90%+104.76%-5.35%LNAILunai Bioworks-3.27%-19.93%-10.23%+48.42%+236,999,900.00%MBRXMoleculin Biotech+2.92%-6.44%0.00%+25.38%-85.25%VIVSVivoSim Labs-0.83%-7.75%-14.39%-37.37%-35.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.00-0.3%$3.24$1.03▼$8.48$13.03M1.7843,278 shs23,861 shsLNAILunai Bioworks$2.29-3.4%$2.63$1.21▼$33.50$10.74M0.4140,538 shs22,046 shsMBRXMoleculin Biotech$2.41-2.4%$2.44$1.79▼$24.00$13.18M1.77290,995 shs172,928 shsVIVSVivoSim Labs$1.19$1.41$1.13▼$5.30$3.10M1.3852,469 shs38,431 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+1.01%-2.27%-2.90%+104.76%-5.35%LNAILunai Bioworks-3.27%-19.93%-10.23%+48.42%+236,999,900.00%MBRXMoleculin Biotech+2.92%-6.44%0.00%+25.38%-85.25%VIVSVivoSim Labs-0.83%-7.75%-14.39%-37.37%-35.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion Therapeutics 1.00SellN/AN/ALNAILunai Bioworks 1.00SellN/AN/AMBRXMoleculin Biotech 2.33Hold$22.00812.86% UpsideVIVSVivoSim Labs 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest VIVS, MBRX, LNAI, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026VIVSVivoSim Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026VIVSVivoSim Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026CYCNCyclerion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026MBRXMoleculin Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026LNAILunai Bioworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/24/2026MBRXMoleculin Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.00(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$2.07M6.28N/AN/A$2.31 per share1.30LNAILunai BioworksN/AN/AN/AN/A($9.92) per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$4.69 per shareN/AVIVSVivoSim Labs$140K22.19N/AN/A$5.54 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$3.53M-$1.36N/AN/AN/A-170.11%-62.10%-55.14%8/4/2026 (Estimated)LNAILunai Bioworks-$178.01M-$0.40N/AN/AN/AN/A-1,243.45%-1,617.76%N/AMBRXMoleculin Biotech-$33.56M-$17.98N/AN/AN/AN/AN/A-70.93%8/11/2026 (Estimated)VIVSVivoSim Labs-$2.48M-$3.15N/AN/AN/A-861.27%-15.51%-11.31%N/ALatest VIVS, MBRX, LNAI, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q3 2026LNAILunai BioworksN/A-$0.80N/A-$0.10N/A$0.02 million5/14/2026Q1 2026MBRXMoleculin Biotech-$2.3333-$3.54-$1.2067-$3.54N/AN/A5/12/2026Q1 2026CYCNCyclerion Therapeutics-$17.20-$0.76+$16.44-$0.76$0.88 millionN/A3/30/2026Q4 2025CYCNCyclerion Therapeutics-$0.38-$0.19+$0.19-$0.19$0.10 million$1.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/ALNAILunai BioworksN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A1.801.80LNAILunai BioworksN/A0.190.19MBRXMoleculin BiotechN/A1.381.38VIVSVivoSim LabsN/A2.442.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%LNAILunai Bioworks71.41%MBRXMoleculin Biotech15.52%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics34.30%LNAILunai Bioworks0.50%MBRXMoleculin Biotech1.10%VIVSVivoSim Labs2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics304.33 million2.85 millionNo DataLNAILunai Bioworks204.53 million4.51 millionN/AMBRXMoleculin Biotech205.34 million5.28 millionNot OptionableVIVSVivoSim Labs202.61 million2.54 millionN/AVIVS, MBRX, LNAI, and CYCN HeadlinesRecent News About These CompaniesVivoSim Labs Inc VIVSMay 17, 2026 | morningstar.comMVivoSim Labs IncMay 14, 2026 | cnn.comVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human ...April 30, 2026 | bakersfield.comBVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | financialpost.comFVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) Real TimeApril 7, 2026 | nasdaq.comVivoSim Announces Pricing of up to a $4 Million Public OfferingApril 1, 2026 | financialpost.comFVivoSim Announces Pricing of up to a $4 Million Public OfferingApril 1, 2026 | globenewswire.comVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsMarch 24, 2026 | financialpost.comFVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsMarch 24, 2026 | globenewswire.comVivoSim Labs Stock Price HistoryMarch 4, 2026 | investing.comVivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 4, 2026 | finanznachrichten.deVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 3, 2026 | financialpost.comFVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 3, 2026 | globenewswire.comVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoFebruary 11, 2026 | financialpost.comFVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoFebruary 11, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) Analyst ResearchFebruary 4, 2026 | nasdaq.comWhy is VIVS stock up 79% today?January 30, 2026 | msn.comVivoSim Labs Expands Commercial Presence in Asia-Pacific with Distribution Agreements in Korea and China for NAMKind™ Toxicology ServicesJanuary 29, 2026 | quiverquant.comQVivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaJanuary 29, 2026 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVIVS, MBRX, LNAI, and CYCN Company DescriptionsCyclerion Therapeutics NASDAQ:CYCN$3.00 -0.01 (-0.33%) Closing price 04:00 PM EasternExtended Trading$3.01 +0.01 (+0.33%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Lunai Bioworks NASDAQ:LNAI$2.29 -0.08 (-3.38%) Closing price 04:00 PM EasternExtended Trading$2.32 +0.02 (+1.09%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.Moleculin Biotech NASDAQ:MBRX$2.41 -0.06 (-2.43%) Closing price 04:00 PM EasternExtended Trading$2.39 -0.02 (-0.71%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.VivoSim Labs NASDAQ:VIVS$1.19 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.16 -0.03 (-2.44%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
